ASLAN Pharma says Bristol-Myers Squibb will Reacquire Cancer Drug

According to Singapore's ASLAN Pharma, Bristol-Myers Squibb will reacquire the rights to ASLAN002, a dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint. BMS will make a $10 million upfront payment and will pay up to $50 million in development and regulatory milestones. ASLAN will also be eligible to receive royalties on global sales of the molecule. ASLAN in-licensed China rights (plus selected Asian countries) to ASLAN002 in 2011. In March of this year. ASLAN reported positive results from a Phase I trial of the drug candidate. More details.... Stock Symbol: (NYSE: BMY) Share this with colleagues: // //